Lipoprotein(a) Measurement and Management

Primary Indications for Lp(a) Testing

The European Society of Cardiology recommends measuring Lipoprotein(a) at least once in patients with premature cardiovascular disease or stroke, especially when traditional risk factors don't fully explain the disease, those with a family history of premature CAD, patients with familial hypercholesterolemia, individuals at intermediate cardiovascular risk by standard calculators, and those with recurrent vascular events despite optimal medical therapy 1, 2, 3
Patients with a family history of premature CAD should have Lp(a) measured, particularly first-degree relatives with premature atherosclerotic CVD or those with Lp(a) levels >200 nmol/L 3
The European Heart Journal suggests that all patients with familial hypercholesterolemia (FH) or other genetic dyslipidemia should have Lp(a) measured 1, 2
Intermediate cardiovascular risk by standard calculators, such as Framingham, PROCAM, ESC Heart Score, or Australian/New Zealand risk calculators, warrants Lp(a) measurement, as levels >50 mg/dL may justify reclassification into a higher risk category 1, 2, 4
The European consensus threshold of 10-year risk of fatal CVD ≥3% according to European guidelines also warrants Lp(a) measurement 1, 2, 4

Recurrent or rapidly progressive vascular disease, especially in patients already on lipid-lowering medication, should have Lp(a) measured repeatedly at regular intervals 1, 2, 5
Patients with low HDL-cholesterol, genetic defects in hemostasis or homocysteine metabolism, diabetes mellitus, autoimmune diseases, renal disease, and hemodialysis patients should have Lp(a) assessed 1, 2, 4

The American College of Cardiology Foundation/American Heart Association guidelines found continuous, independent associations of Lp(a) with increased risk for CHD and stroke, based on 36 prospective studies involving >125,000 participants 6, 7, 8
Elevated Lp(a) and LDL cholesterol confer a 10-fold or higher risk of myocardial infarction compared to those with normal levels 5, 3

Intensive treatment of traditional modifiable risk factors, especially LDL cholesterol, is justified by the additional risk conferred by elevated Lp(a), with lower LDL-C goals 1, 2, 3, 7, 8

The European Heart Society recommends measuring Lipoprotein(a) in patients with premature cardiovascular disease or stroke, particularly when traditional risk factors fail to explain the vascular disease 9
Patients with familial hypercholesterolemia require Lipoprotein(a) measurement, as they face compounded cardiovascular risk and potential aortic valve calcification 9
Hemodialysis and chronic kidney disease patients should be screened, as Lipoprotein(a) levels are 2-3 fold elevated in these populations and independently predict cardiovascular events 9

Elevated Lipoprotein(a) is defined as >30 mg/dL, representing the 75th percentile in white populations where cardiovascular risk demonstrably increases, although the European guidelines use >50 mg/dL as the threshold for significant risk requiring reclassification 9